The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Phase 3 Studies Evaluate Lesinurad for Gout Treatment

Phase 3 Studies Evaluate Lesinurad for Gout Treatment

July 15, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270In the CLEAR 1 study presented June 12 at the 2015 meeting of the European League Against Rheumatism (EULAR), researchers investigated lesinurad, a selective uric acid reabsorption inhibitor (SURI), combined with xanthine oxidase inhibitors, for treating gout.1

You Might Also Like
  • FDA Approves Lesinurad + Allopurinol
  • Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout
Also By This Author
  • Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis

Patients with an inadequate response to standard care were randomized to receive 200 mg (n = 201) or 400 mg (n = 201) of lesinurad daily in combination with allopurinol or allopurinol plus placebo (n = 201). This 12-month, randomized, double-blind, Phase 3 study involved patients 18–85 years old on stable, appropriate allopurinol doses, ranging from 200–600 mg—most receiving 300 mg. At study screening, all patients had a serum uric acid (sUA) level ≥ 6.5 mg/dL and had two or more gout flares in the previous year. The baseline sUA measurement was 6.94 ± 1.27 mg/dL, with 14.3% having tophi.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The primary endpoint was the proportion of patients achieving the sUA target of < 6.0 mg/dL by Month 6. Secondary endpoints were mean gout flare rate requiring treatment (GFRT, Months 6–12) and the proportion of patients with complete resolution of one or more target tophi by Month 12. Treatment-emergent adverse events and laboratory data were assessed.

Both lesinurad-treated groups had significantly increased proportions of patients achieving sUA targets compared with placebo plus allopurinol-treated patients. Approximately twice as many patients achieved these targets at Month 6. At Month 6, sUA < 6 mg/dL, lesinurad 200 mg results were 54%, lesinurad 400 mg results were 59% and placebo results were 28%. The majority of patients were male (94%) with a mean ± SD age of 51.9 ± 11.3 years and a duration of gout disease of 11.8 ± 9.4 years. There were no significant differences observed between groups in mean rate of GFRT (Month 6–12) or patients with complete target tophus resolution (by Month 12).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The percentage of patients developing serious treatment-emergent adverse events (TEAEs) or serious renal-related TEAEs was comparable between the 200 mg lesinurad group and the placebo-treated group. Patients who received 400 mg lesinurad had twice as many serious TEAEs or serious renal-related TEAEs. Additionally, more patients treated with 400 mg lesinurad developed a more-than-two-times increase in the serum creatinine (6% vs. 1% of 200 mg lesinurad-treated and 0% of placebo-treated patients). Most of the serum creatinine elevations resolved without stopping lesinurad. Lesinurad was generally well tolerated with a good clinical response.

In a CLEAR 2 study also presented at EULAR, Bardin et al evaluated the same study population and parameters with similar results.2 The majority of patients (n = 610) were male (96.2%) with a mean ± SD age of 51.2 ± 10.9 years and a duration of gout disease of 11.5 ± 9.3 years. Allopurinol doses ranged from 200–900 mg, with most receiving 300 mg.

Baseline sUA measurement was 6.90 ± 1.19 mg/dL, with 23.6% having tophi. Both lesinurad-treated groups had significantly increased proportions of patients achieving sUA targets compared with placebo plus allopurinol-treated patients. Approximately twice as many patients achieved these targets at Month 6. At Month 6, sUA < 6 mg/dL, lesinurad 200 mg results were 54%, lesinurad 400 mg results were 59% and placebo results were 23%. There were no significant differences observed between groups in mean rate of GFRT or with complete target tophus resolution. Safety was similar to CLEAR 1. Lesinurad combined with allopurinol was well tolerated and met study endpoints without severe toxicity.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Saag K, Fitz-Patrick D, Kopicko J, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: Results from a phase 3 study in gout patients having an inadequate response to standard of care (CLEAR 1). Ann Rheum Dis. 2015 June; 74(Suppl2):540. Abstract FRI0320. doi: 10.1136/annrheumdis-2015-EULAR.3273
  2. Bardin T, Keenan R, Khanna P, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: Results from a phase 3 study in gout patients having an inadequate response to standard of care (CLEAR 2). Ann Rheum Dis. 2015 June; 74(Suppl2):545. Abstract FRI0333. doi: 10.1136/annrheumdis-2015-EULAR.1238

Pages: 1 2 | Multi-Page

Filed Under: Conditions, Crystal Arthritis, Drug Updates Tagged With: Allopurinol, EULAR, Gout, lesinurad

You Might Also Like:
  • FDA Approves Lesinurad + Allopurinol
  • Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout
  • The ACR’s & EULAR’s Gout Guidelines Include Treatment Approaches

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)